Transthyretin Amyloid Cardiomyopathy Treatment Market Estimated to Witness High Growth Owing to Increasing Drug Approvals and Launch of Novel Therapies
The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market is estimated to be valued at US$ 1.98 billion in 2027 and is expected to exhibit a CAGR of 31.1% over the forecast period 2020-2027, as highlighted in a new report published by Coherent Market Insights. Market Overview:Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, progressive heart muscle disease … Read more